<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18654">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02864043</url>
  </required_header>
  <id_info>
    <org_study_id>16-01</org_study_id>
    <nct_id>NCT02864043</nct_id>
  </id_info>
  <brief_title>Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System</brief_title>
  <acronym>DDP</acronym>
  <official_title>Identification of Features Associated With Dysplasia Using the NvisionVLE® Imaging System Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NinePoint Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NinePoint Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NvisionVLE® Dysplasia Detection Pilot Study is a collection of data for research.
      Participation is completely voluntary and does not affect the patient's medical care that
      chooses not to participate. The purpose of this Study is to determine the performance of the
      NvisionVLE® Imaging System in determining features of dysplastic Barrett's Esophagus (BE).
      This is done by the collection and analysis of the medical record information, imaging data,
      and pathology results. The information is then stored and may be used at a later time for
      various future analyses and publications. Any future analyses involving this Study will only
      use the information collected in this Study. No further involvement or additional informed
      consent of participants will be needed if future analyses are performed.

      This Study is designed for participants who have a prior biopsy-confirmed diagnosis of BE
      with dysplasia and are scheduled to have an endoscopic evaluation of your esophagus for BE
      surveillance by a standard procedure called EGD (esophagogastroduodenoscopy) as well as an
      imaging procedure called VLE (volumetric laser endomicroscopy).

      The NvisionVLE® Imaging System is cleared for use by the U.S. Food and Drug Administration
      (FDA).

      Patients who undergo an endoscopic evaluation of the esophagus with the NvisionVLE® Imaging
      System at participating hospitals will be invited to participate in this Study. The Study is
      taking place at up to 4 hospitals, and as many as 100 patients may participate in this
      Study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of manually identified VLE features in predicting biopsy defined dysplasia</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of VLE criteria for detecting dysplasia</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Barrett's Esophagus</condition>
  <arm_group>
    <arm_group_label>NvisionVLE imaging with Real Time Targeting</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NvisionVLE imaging with Real Time Targeting</intervention_name>
    <description>Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe</description>
    <arm_group_label>NvisionVLE imaging with Real Time Targeting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over the age of 18.

          -  Patients undergoing an upper endoscopy for BE surveillance with prior
             biopsy-confirmed BE with dysplasia (at least LGD).

          -  Ability to provide written, informed consent.

          -  No significant esophagitis (LA grade &lt; B, C and D).

        Exclusion Criteria:

          -  Patients who have achieved complete remission of intestinal metaplasia (CR-IM)

          -  Patients without visible BE at time of study EGD.

          -  Patients for whom use of the NvisionVLE device would be in conflict with the
             Instructions for Use (IFU).

          -  Prior esophageal or gastric surgical resection.

          -  Significant esophageal stricture requiring dilatation.

          -  Patients who require anticoagulation for whom biopsy would be contraindicated.

          -  Patients who are known to be pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Simon C Schlachter, PhD</last_name>
    <phone>+1-617-250-7190</phone>
    <email>SSchlachter@ninepointmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amna R Soomro</last_name>
    <phone>+1-617-250-7190</phone>
    <email>asoomro@ninepointmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Irvine Medical Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sentelle Eubanks</last_name>
      <phone>714-456-2215</phone>
    </contact>
    <investigator>
      <last_name>Kenneth J Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Lutzke</last_name>
      <phone>505-255-7495</phone>
    </contact>
    <investigator>
      <last_name>Kenneth K Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benley George</last_name>
      <phone>781-470-7997</phone>
    </contact>
    <investigator>
      <last_name>Arvind J Trindade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Roberts</last_name>
      <phone>215-707-2498</phone>
    </contact>
    <investigator>
      <last_name>Michael Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 14, 2016</lastchanged_date>
  <firstreceived_date>August 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Barrett's Esophagus</keyword>
  <keyword>Barrett's</keyword>
  <keyword>OCT</keyword>
  <keyword>VLE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
